文献速递呼吸道感染

双肺移植受者多重耐药及超广谱β-内酰胺酶革兰阴性菌:发生率、危险因素与院内死亡率

Multidrug-Resistant and Extended-Spectrum β-Lactamase Gram-Negative Bacteria in Bilateral Lung Transplant Recipients: Incidence, Risk Factors, and In-Hospital Mortality.
PubMed 文献 · Chest · 2022-07-16

该回顾性研究纳入132例首次双肺移植受者,术后30天内34%检出MDR或ESBL革兰阴性菌,其中60%为临床相关感染。既往定植和经验性使用广谱抗生素是独立预测因素,MDR/ESBL组院内死亡率为27%,死亡风险显著增高。

要点

  • 双肺移植后30天内MDR/ESBL革兰阴性菌检出率达34%,以铜绿假单胞菌和肺炎克雷伯菌为主。
  • 既往受体定植和经验性广谱抗生素暴露是MDR/ESBL菌检出的独立预测因素。
  • MDR/ESBL组院内死亡率为27%,死亡风险约为非MDR/ESBL组的6倍。

核心结论

  • 双肺移植后MDR和ESBL革兰阴性菌发生率为34%,相关院内死亡风险显著增高。
  • 既往受体定植和经验性广谱抗生素暴露是MDR/ESBL革兰阴性菌检出的临床预测因素。

研究设计与样本

  • 纳入标准为成人、首次双肺移植、术前无需有创机械通气或体外膜肺氧合。
  • MDR和ESBL革兰阴性菌通过体外药敏试验鉴定,标本来自呼吸道、血液、尿液、直肠拭子、手术伤口或引流液。

主要发现

  • 132例受者中45例(34%)检出MDR和ESBL革兰阴性菌,其中60%为临床相关感染。
  • 常见菌为铜绿假单胞菌22例(49%)和肺炎克雷伯菌17例(38%),标本多来自呼吸道21例(47%)和多部位18例(40%)。

临床怎么用

  • 对双肺移植受者应关注既往定植史和经验性广谱抗生素使用,以识别MDR/ESBL革兰阴性菌高风险人群。
  • 术后30天内应加强呼吸道等多部位MDR/ESBL革兰阴性菌监测,以早期发现感染并干预。

局限性

  • 本研究为单中心回顾性设计,样本来自单一移植中心,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In recent decades, the incidence of multidrug-resistant (MDR) and extended-spectrum β-lactamase (ESBL) gram-negative (GN) bacteria has increased progressively among lung transplantation (LT) recipients. A prompt diagnosis, prevention, and management of these pathogens remain the cornerstone for successful organ transplantation. RESEARCH QUESTION: What are the incidence of MDR and ESBL GN bacteria within the first 30 days after LT and related risk of in-hospital mortality? What are the potential clinical predictors of isolation of MDR and ESBL GN bacteria? STUDY DESIGN AND METHODS: All consecutive LT recipients admitted to the ICU of the University Hospital of Padua (February 2016-December 2021) were screened retrospectively. Only adult patients undergoing the first bilateral LT and not requiring invasive mechanical ventilation, extracorporeal membrane oxygenation, or both before surgery were included. MDR and ESBL GN bacteria were identified using in vitro susceptibility tests and were isolated from the respiratory tract, blood, urine, rectal swab, or surgical wound or drainage according to a routine protocol. RESULTS: One hundred fifty-three LT recipients were screened, and 132 were considered for analysis. Median age was 52 years (interquartile range, 41-60 years) and 46 patients (35%) were women. MDR and ESBL GN bacteria were identified in 45 patients (34%), and 60% of patients demonstrated clinically relevant infection. Pseudomonas aeruginosa (n = 22 [49%]) and Klebsiella pneumoniae (n = 17 [38%]) were frequently isolated after LT from the respiratory tract (n = 21 [47%]) and multiple sites (n = 18 [40%]). Previous recipient-related colonization (hazard ratio [HR], 2.48 [95% CI, 1.04-5.90]; P = .04) and empirical exposure to broad-spectrum antibiotics (HR, 6.94 [95% CI, 2.93-16.46]; P < .01) were independent predictors of isolation of MDR and ESBL GN bacteria. In-hospital mortality of the MDR and ESBL group was 27% (HR, 6.38 [95% CI, 1.98-20.63]; P < .01). INTERPRETATION: The incidence of MDR and ESBL GN bacteria after LT was 34%, and in-hospital mortality was six times greater. Previous recipient-related colonization and empirical exposure to broad-spectrum antibiotics were clinical predictors of isolation of MDR and ESBL GN bacteria.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Boscolo A, Sella N, Pettenuzzo T, et al. Multidrug-Resistant and Extended-Spectrum β-Lactamase Gram-Negative Bacteria in Bilateral Lung Transplant Recipients: Incidence, Risk Factors, and In-Hospital Mortality. Chest. 2022. PMID: 35850288. doi:10.1016/j.chest.2022.06.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。